Orphazyme A/S (ORPHA.CO)

DKK 1120.0

(-2.61%)

Long Term Debt Summary of Orphazyme A/S

  • Orphazyme A/S's latest annual long term debt in 2023 was - DKK , down 0.0% from previous year.
  • Orphazyme A/S's latest quarterly long term debt in 2024 Q2 was - DKK , down 0.0% from previous quarter.
  • Orphazyme A/S reported annual long term debt of - DKK in 2022, down -100.0% from previous year.
  • Orphazyme A/S reported annual long term debt of 6.4 Million DKK in 2021, down -80.99% from previous year.
  • Orphazyme A/S reported quarterly long term debt of - DKK for 2024 Q1, down 0.0% from previous quarter.
  • Orphazyme A/S reported quarterly long term debt of - DKK for 2023 Q2, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Orphazyme A/S (2023 - 2013)

Historical Annual Long Term Debt of Orphazyme A/S (2023 - 2013)

Year Long Term Debt Long Term Debt Growth
2023 - DKK 0.0%
2022 - DKK -100.0%
2021 6.4 Million DKK -80.99%
2020 33.7 Million DKK -45.12%
2019 61.41 Million DKK 0.0%
2018 - DKK 0.0%
2017 - DKK 0.0%
2016 - DKK 0.0%
2015 - DKK 0.0%
2014 - DKK 0.0%
2013 - DKK 0.0%

Peer Long Term Debt Comparison of Orphazyme A/S

Name Long Term Debt Long Term Debt Difference
ALK-Abelló A/S 439 Million DKK 100.0%
Bavarian Nordic A/S 15.13 Million DKK 100.0%
Genmab A/S 680 Million DKK 100.0%
Gubra A/S 60.68 Million DKK 100.0%
Novo Nordisk A/S 20.52 Billion DKK 100.0%
Pharma Equity Group A/S 8.07 Million DKK 100.0%
Zealand Pharma A/S 102.57 Million DKK 100.0%